Home/Filings/4/0001493152-23-032275
4//SEC Filing

Werth Peter J. 4

Accession 0001493152-23-032275

CIK 0001862150other

Filed

Sep 10, 8:00 PM ET

Accepted

Sep 11, 5:00 PM ET

Size

8.8 KB

Accession

0001493152-23-032275

Insider Transaction Report

Form 4
Period: 2023-09-08
Transactions
  • Other

    Pre-Funded Warrant (right to buy)

    2023-09-08+6,838,2356,838,235 total(indirect: By LLC)
    Exercise: $0.00From: 2023-09-08Common Stock (6,838,235 underlying)
Transactions
  • Other

    Pre-Funded Warrant (right to buy)

    2023-09-08+6,838,2356,838,235 total(indirect: By LLC)
    Exercise: $0.00From: 2023-09-08Common Stock (6,838,235 underlying)
Footnotes (3)
  • [F1]On August 9, 2022, Cingulate Therapeutics LLC ("CTx"), a wholly-owned subsidiary of the Issuer, issued a Promissory Note (the "Original Note") to Werth Family Investment Associates LLC ("WFIA") with a principal amount of $5,000,000 (the "Original Principal Amount"), and on May 9, 2023, CTx issued an Amended and Restated Promissory Note (the "A&R Note") increasing the principal amount under the Original Note by $3,000,000 to $8,000,000. On September 8, 2023, the Issuer and CTx entered into a Note Conversion Agreement (the "Note Conversion Agreement") with WFIA, pursuant to which WFIA agreed to convert the Original Principal Amount under the A&R Note plus all accrued interest thereon, or $5,812,500, into pre-funded warrants to purchase 6,838,235 shares of common stock of the Issuer, at a conversion price per pre-funded warrant of $0.85
  • [F2]The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer.
  • [F3]Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Documents

1 file

Issuer

Cingulate Inc.

CIK 0001862150

Entity typeother

Related Parties

1
  • filerCIK 0001883257

Filing Metadata

Form type
4
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 5:00 PM ET
Size
8.8 KB